Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.34 USD | -3.20% | +15.37% | +63.18% |
May. 28 | Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday | MT |
May. 28 | Agios Pharmaceuticals to Sell 15% Vorasidenib Royalty Rights to Royalty Pharma for $905 Million | MT |
Evolution of the average Target Price on Agios Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Agios Pharmaceuticals, Inc.
RBC Capital Markets | |
Goldman Sachs | |
JPMorgan Chase | |
Piper Sandler | |
SVB Securities LLC | |
HC Wainwright | |
SVB Leerink | |
Canaccord Genuity | |
BofA Securities | |
Raymond James | |
Barclays | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- AGIO Stock
- Consensus Agios Pharmaceuticals, Inc.